Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Colorectal Cancer
How do you approach adjuvant chemotherapy in resected T4N0 colon cancer?
Related Questions
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
Why does NCCN still not recommend using circulating tumor DNA to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?
What would be your radiotherapy plan for an overall stage IIA, low-lying, MMRd rectal adenocarcinoma to try to avoid APR?
Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
